EP3315124A1 — Bilayer tablet formulations
Assigned to AstraZeneca UK Ltd · Expires 2018-05-02 · 8y expired
What this patent protects
The present invention relates to bilayer tablets comprising a metformin hydrochloride formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention further relates to medical uses of said bilayer tablets a…
USPTO Abstract
The present invention relates to bilayer tablets comprising a metformin hydrochloride formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention further relates to medical uses of said bilayer tablets and to pharmaceutical combinations comprising said bilayer tablets.
Drugs covered by this patent
- Farxiga (DAPAGLIFLOZIN) · AstraZeneca
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.